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Effects of fibrillin mutations 
on the behavior of heart muscle 
cells in Marfan syndrome
Jeffrey Aalders1, Laurens Léger1, Louis Van der Meeren2, Natasja Van den Vreken1, 
Andre G. Skirtach2, Sanjay Sinha3, Julie De Backer4 & Jolanda van Hengel 1*
Marfan syndrome (MFS) is a systemic disorder of connective tissue caused by pathogenic variants 
in the fibrillin-1 (FBN1) gene. Myocardial dysfunction has been demonstrated in MFS patients and 
mouse models, but little is known about the intrinsic effect on the cardiomyocytes (CMs). In this study, 
both induced pluripotent stem cells derived from a MFS-patient and the line with the corrected FBN1 
mutation were differentiated to CMs. Several functional analyses are performed on this model to study 
MFS related cardiomyopathy. Atomic force microscopy revealed that MFS CMs are stiffer compared to 
corrected CMs. The contraction amplitude of MFS CMs is decreased compared to corrected CMs. Under 
normal culture conditions, MFS CMs show a lower beat-to-beat variability compared to corrected 
CMs using multi electrode array. Isoproterenol-induced stress or cyclic strain demonstrates lack of 
support from the matrix in MFS CMs. This study reports the first cardiac cell culture model for MFS, 
revealing abnormalities in the behavior of MFS CMs that are related to matrix defects. Based on these 
results, we postulate that impaired support from the extracellular environment plays a key role in the 
improper functioning of CMs in MFS.
Marfan syndrome (MFS) is a rare systemic disorder of the connective tissue with an estimated prevalence of 
1:5000–1:10,0001. Typically, multiple organ systems are affected in MFS patients, with manifestations in the 
skeletal, ocular, integumentary, respiratory and cardiovascular  system2. Aortic complications due to progres-
sive aortic dilation leading to potential aneurysm, dissection, and rupture are the main cause of morbidity and 
mortality in patients with MFS.
Pathogenic variants in the FBN1 gene, coding for fibrillin-1, are causative for  MFS3. Fibrillin-1 is a major 
component of the microfibrils that are important in the extracellular matrix (ECM) including the ECM of elastic 
tissues such as the  aorta4. The localization of fibrillin-1 in the heart also suggests a role for fibrillin-1 in myocardial 
 tissue5. Due to pathogenic variants in FBN1, elastic fiber composition is suboptimal and compensated by excessive 
collagen and proteoglycan deposition, which leads to increased stiffness and progressive weakening of the  ECM6.
In addition to structural and mechanical support, fibrillin-1 also exhibits regulatory activities in growth fac-
tor signaling, ECM formation, cell behavior and the immune  response7. Microfibrils normally act as docking 
sites for latent TGF-ß complexes, however, pathogenic variants in FBN1 result in release and activation of the 
normally bound TGF-ß8. While increased TGF-ß signaling is a hallmark of MFS, uncertainty remains about the 
molecular mechanisms and disease  progression9,10.
While aortic complications are still the leading cause of MFS-related mortality, advances in medical and 
surgical management have improved life  expectancy11. Due to this increased life expectancy, other clinical 
manifestations have arisen, among which is myocardial  involvement12. Myocardial dysfunction secondary to 
significant valvular disease is a well-known cardiovascular complication in  MFS13–15. However, several independ-
ent studies have provided evidence for MFS-related cardiomyopathy unrelated to valvular disease, leading to the 
term Marfan  cardiomyopathy12,16–18.
While FBN1 appears causative for MFS cardiomyopathy, these studies also warrant the necessity for a better 
understanding of the underlying mechanisms. An approach to study MFS cardiomyopathy could be by collecting 
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CMs from MFS patients during surgery, transplantation or biopsy, but this is a rather invasive and limiting 
method to study the disease. In vivo mouse models for MFS with fibrillin-1 deficiency have led to an increased 
understanding of MFS. Abnormal mechanosignaling by CMs has been observed in mouse models for MFS that 
can lead to dilated cardiomyopathy, thus implying an intrinsic  cardiomyopathy14. However, the mouse model has 
some limitations. For instance the beat rate of the mouse heart differs from that of the human  heart19.
An alternative approach to in vivo human studies and animal studies is through the generation of stem cell 
derived CMs. Somatic cells of MFS patients could be reprogrammed to human pluripotent stem cells (hiPSCs)20. 
An unlimited supply of CMs can be differentiated from hiPSCs with good potential for an in vitro model that 
resembles the human cardiac tissue and accurately recapitulates the human cardiac  pathophysiology21. This 
approach has led to improved understanding of various other genetic  cardiomyopathies22–24. However, to the 
best of our knowledge, no in vitro cardiac model has been described for MFS. An in vitro cell model offers the 
possibility to analyze specific cell types outside their complex biological context and excludes in vivo masking 
factors such as the effect of specific medical treatment.
The hiPSC strategy has been employed previously to establish a vascular model of MFS, which investigated 
disease mechanisms in smooth muscle  cells25. This current study reports the functional characterization of the 
in vitro MFS cardiac model that was derived by differentiating hiPSCs to CMs. The established in vitro cardiac 
model for MFS was studied by means of multi electrode array (MEA), cyclic strain imparted with the Flexcell, 
atomic force microscopy (AFM) and video analysis, revealing abnormalities in the behavior of MFS CMs.
Material and methods
All products used are purchased from Life Technologies unless mentioned otherwise.
Culture of hiPSCs. hiPSCs MFS and hiPSCs corrected lines were obtained via prof. S. Sinha (University of 
Cambridge) which were previously generated and characterized by his  group25. These are isogenic lines; MFS 
harbors a FBN1 mutation in exon 30 (c.3725G > A), while in the corrected hiPSCs this mutation was repaired 
using CRISPR-Cas9. For CRISPR-Cas9, a donor plasmid with intronic homology arms 1,063 bp upstream and 
970 bp downstream of exon 30 was used for specific homology direct repair for the mutant allele CYS1242TYR. 
These cell lines were originally cultured on mitomycin-C-treated MEFs in hiPSC medium and maintained at 
37 °C, 5%  CO2 and 5%  O2. hiPSC medium contained: DMEM/F12 (Cat No. 31330038), 20% Knock-out serum 
replacement (Cat No. 10828028), 2 mM l-glutamine (Cat No. 25030081), 1% Non-essential amino acids (Cat 
No. 11140-050), 0.1 mM β-mercapthoethanol (Cat No. 31350010), 100 u/ml Penicillin and 100 µg/ml Strep-
tomycin ((P/S) Cat No. 15140-122) and further supplemented with 4  ng/ml bFGF-2 (PeproTech, Cat No. 
100-18B-10UG). Cultures were adapted to feeder-free conditions using Geltrex coating (Cat No. A1413302) 
and cultured in Essential 8 medium (Cat No. A1517001) supplemented with P/S with a seeding density of 
2.1 × 104 cells/cm2 26. The H9 human embryonic stem cell (hESC) line (WA09, WiCell, feeder free cultures were 
obtained via prof. C. Verfaillie, KULeuven, Belgium) was cultured feeder-free in Essential 8 medium under the 
same conditions as the MFS and corrected lines and was used as control.
Differentiation to cardiomyocytes. For the derivation of CMs from hiPSCs and H9 stem cells, the PSC 
Cardiomyocyte Differentiation Kit (Cat No. A2921201) was used, the manufacturer’s protocol was slightly modi-
fied. In short, hiPSCs were transferred in clumps using Versene/EDTA (Lonza, Cat No. 17-711E) to a Geltrex 
coated 12-well with a seeding density of 5.7 × 104 cells/cm2. After 2 days, the Essential 8 medium was supple-
mented with 1:100 Geltrex to create a sandwich overlay. After 3 days (at 70–80% confluence) the cells were 
washed with PBS and the differentiation was induced according to the protocol of the PSC Cardiomyocyte 
Differentiation Kit. From day 4 of differentiation the cells were kept in maintenance medium and medium was 
refreshed every 48 h.
Passaging of cardiomyocytes. In vitro derived CMs were passaged for subsequent experiments using 
TrypLE select enzyme (Cat No. 12563011). CM cell cultures were washed with PBS and subsequently incubated 
for 5 min with TrypLE at 37 °C. Cells were dissociated by pipetting gently up and down and TrypLE was inac-
tivated by diluting in maintenance medium. Cell suspension was centrifuged for 5 min at 200×g, and pellet was 
dissolved in maintenance medium supplemented with 1:100 RevitaCell (Cat No. A2644501) and 1:100 Geltrex 
for 2 days with a seeding density of 2 × 105 cells/cm2. Maintenance medium was then refreshed every 48 h.
Immunohistochemical analysis of stem cells and cardiomyocytes. hiPSCs and CMs were fixed 
for 20 min with 4% paraformaldehyde at RT. hiPSCs were permeabilized for 30 min with 0.1% Triton ×-100 
diluted in phosphate buffered saline (PBS). Subsequent incubation with blocking solution consisting of 5% Goat 
serum (Cat No. 16210-064) in PBS was done for 30 min. The cells were incubated overnight at 4 °C with primary 
antibodies diluted in PBS containing 0.05% Tween20 and 1% bovine serum albumin (BSA). The used antibod-
ies are listed in Supplementary Table 1. The next day, the cells were incubated for 30 min at RT with secondary 
antibodies diluted in PBS containing 0.05% Tween20 and 1% BSA and subsequently incubated for 10 min with 
0.1% Hoechst solution (Cat No. H3570). The immunostaining of CMs was performed as previously described 
with the exception that the primary antibody was incubated overnight at 4°C27. Microscopy images were made 
using the EVOS FL Imaging System or the ZEISS LSM900 confocal microscope.
Gene expression analysis of cardiomyocytes. RNA extraction was performed from cell cultures 
at day 15 and 24 after start of differentiation to CMs in accordance with the manufacturer’s protocols using 
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GeneElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich, Cat No. RTN70) including on-column DNA 
digestion. RNA was converted to cDNA using the SuperScript III First-Strand Synthesis SuperMix-kit (Invit-
rogen, Cat No. 18080400). qPCR was performed using the Platinum SYBR Green qPCR SuperMix-UDG-kit 
(Cat No. 11733038) on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) using the following PCR 
protocol: 2 min 50 °C, 2 min 95 °C followed by 40 cycles of 20 s 95 °C and 45 s 60 °C on 10 ng cDNA per 20 µl 
reaction. Primers were used at a final concentration of 200 nM (Supplementary Table 2). Analysis of qPCR 
results was performed using CFX Manager-software (Bio-Rad).
Atomic force microscopy. All AFM measurements were executed with the bio-AFM: Nanowizard 4 (JPK 
instruments). For these measurements, the DNP-S10 (Bruker) chip was used. On this chip, a V-shaped cantile-
ver B was chosen, which has a nominal spring constant of 0.06 N/m and a nominal radius of curvature of 10 nm. 
High resolution images were made using the special Quantitative imaging (QI) mode, which allowed the acqui-
sition of the mechanical properties of each pixel upon scanning. Large scale force maps were measured in the 
contact mode. All the measurements were executed with setpoints ranging from 2 to 5 nN. The AFM instrument 
was mounted on top of an inverted microscope (Zeiss) facilitating the localization of tissues. Areas of interest 
were selected based on morphology to ensure that representative parts of the culture were assessed. Further-
more, an in-house built incubator was mounted around the AFM, providing a 37 °C and 5%  CO2 environment, 
permitting prolonged measurements without affecting cells.
The software used to acquire and process the AFM data was provided by the instrument manufacturer: JPK-
SPM version 6.1.165 (JPK BioAFM, Bruker, https ://www.jpk.com/). Based on force curves, the Young’s modulus 
was calculated using the Hertz/Sneddon model adjusted for parabolic  indenters28,29. After Young’s modulus cal-
culation, the elasticity data was further normalized and filtered in MATLAB version R2019b Update 6. Statistical 
data analysis was performed in R-studio (version 3.5.0) using the Welch-two-sample T-test.
CMs grow as a layer on top of a basal layer, and showed as a distinct population in the AFM measurements. 
20-day-old CMs were passaged to 35 mm plastic petri dishes and were analyzed after a 5 day recovery period. 
The beating of CMs was stopped directly before AFM measurements using a 40 mM KCl solution. In order to 
obtain mechanical information of this heart cell population, the Young’s modulus of the top 25% highest points 
in the QI-maps was compared to the overall average Young’s modulus of each cell line. To acquire this data, 
points obtained in the QI-force-height maps were pooled together for each cell line. From this pool, the average 
Young’s modulus was determined. Furthermore, the maximum height was determined and consequently the 
highest 25% was selected. Using the corresponding Young’s modulus of this selected highest 25%, the average 
Young’s modulus was recalculated and compared to the previous average calculated on the whole population.
Video analysis using Musclemotion software. Musclemotion software was used to investigate differ-
ence in contraction between the corrected and MFS  CMs30. Short video clips of 30 frames/s were made from 
beating corrected and MFS CMs for 60 s for three independent cell cultures per line. The algorithm used in this 
software compares the pixel intensity of each frame with a reference frame. The difference measured between 
each pixel in the reference frame and the pixel in the frame of interest, is given as output in absolute numbers. 
This number represents the change of displacement in time, and correlates with the contraction amplitude.
Multi electrode array. Multi electrode array measurements were performed with a 6-well MEA (Multi 
Channel Systems, 60-6wellMEA200/30iR-Ti-rcr) on a USB-MEA-128 system with a MEA1060BC amplifier 
(Multi Channel Systems). Electrodes of each 6-well were coated with a 10 µl drop of 25 µg/ml fibronectin (Pro-
moCell, Cat No. C-43060) for 1  h at 37  °C. Approximately 30.000 CMs (15–20  days old) were seeded onto 
those drops. After a recovery period of 5 days, baseline recordings measuring the extracellular electrograms of 
spontaneously contracting CMs were made for 180 s using the Cardio2D software (Multi Channel Systems). 
The temperature was kept at 37 °C using a heating element and a temperature controller. One electrode with the 
best signal was selected per well for subsequent analysis. Automatic beat detection was used in the Multi-well 
analyzer software (Multi Channel Systems) to derive RR intervals. The RR interval is the time between two con-
secutive membrane depolarizations, indicating the beat-to-beat duration. SDNN was calculated as the standard 
deviation of all the RR intervals. The SDSD was calculated as the standard deviation of the successive RR interval 
differences. Coefficient of variance is obtained by dividing the SDNN by the average RR interval.
Isoproterenol treatment. Isoproterenol (ISO, Sigma-Aldrich, Cat No. I6504) was diluted to a 3 mM stock 
in distilled water and filtered with a 0.2 μm filter. Stock solution was freshly diluted in maintenance medium 
and only a maximum of 5 μl compound was added, minimizing medium changing effects. CMs were stimulated 
with increasing concentration (5 nM, 10 nM, 25 nM, 50 nM and 100 nM) of ISO. For each dose, extracellular 
electrograms were measured for 60–300 s at a sampling rate of 10,000 Hz.
For the chronic treatment, the medium of CMs was refreshed daily with maintenance medium containing 
1 µM ISO, starting at day 17 for a period of 7 days.
Flexcell. Flexcell FX-5000 Tension system (Flexcell International Corporation) was used to apply mechani-
cal forces on the in vitro cell model. Bioflex 6-well plates were coated with drops (20 µl) of 25 µg/ml fibronectin 
for 1 h at 37 °C. CMs were seeded onto those drops at a density of ∼ 30.000 CMs/drop. CMs were stretched in the 
Flexcell FX-5000 tension system (sinus) with 10% stretch at 1.0 Hz for 6 h and 40 h. As a control, both corrected 
and MFS CMs were cultured on the Flexcell membrane without stretching.
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Statistical analysis. Statistical analysis for MEA data, gene expression levels and contraction amplitude 
derived from the video clips and Spearman’s rank correlation was performed using SPSS statistics version 23.0 
for Windows (IBM Corp., Armonk, NY). Means of normalized expression were compared using unpaired t-test 
and reported as two tailed p value for comparison of two independent means with significance level of 0.05.
Ethics statement. Experiments with hiPSCs were approved by the local ethical committee of Ghent Uni-
versity Hospital (EC UZG 2017/0855).
Results
In this study, an in vitro cardiac model for MFS is established and investigated. CM cell cultures derived from 
hiPSCs carrying a pathogenic variant in FBN1 are compared with CM cell cultures derived from the isogenic 
hiPSCs, where the pathogenic variant is CRISPR-Cas9  corrected25. The cell cultures are respectively named MFS 
and corrected. Furthermore, the hESC H9 line is used in MEA experiments as an additional control.
Cell culture and cardiac differentiation potential not affected by FBN1 variant. The hiPSCs 
cultures of MFS and corrected (Fig. 1A-B) show similar growth characteristics. Passaging of the cultures was 
done every 3–4  days at a confluency of approximately 80% with the same passaging ratio (1:4). Fluorescent 
intensities of OCT4 (2.13 vs 2.05), SOX2 (2.08 vs 1.53) and NANOG (1.40 vs 1.53) relative to HOECHST for 
the corrected and MFS hiPSCs respectively, show that both cell cultures are pluripotent (Fig. 1C,D and suppl. 
Fig. 1). Directed cardiomyocyte differentiation of the hiPSCs leads to beating CMs after 8–12 days after the start 
of differentiation for both MFS and corrected hiPSCs (Fig. 1E,F). In this culture system, the derived CMs grow 
as a contracting layer on top of a basal layer that was formed during the cardiac differentiation. It is presumed 
that the non-contracting basal layer exist predominantly of fibroblasts. The recovery of CMs after passaging is 
observed to be relatively lower for MFS CMs compared to corrected CMs as showed by smaller areas of contrac-
tion (Fig. 1G,H). CMs are passaged only once for subsequent experiments, taking into account this relative lower 
recovery rate of MFS CMs to have similar culture composition in these analyzes. The maturation status of the 
CMs was determined using the relative gene expression of TNNI1 and TNNI3, showing a relatively lower matu-
ration status for MFS CMs compared to corrected CMs at day 15 (Fig. 1I), although not statistically significant 
(p = 0.067). After 24 days of cardiac differentiation, the maturation status of MFS CMs increased, although not 
significantly (p = 0.074) and is similar to the corrected CMs. Moreover, no significant difference in TNNT2 gene 
expression 24 days after cardiac differentiation is observed (Fig. 1J), indicating that the differentiation potential 
of the hiPSCs is not affected by the FBN1 variant.
Defective fibrillin in the MFS cardiomyocyte cell culture confirms ECM defect. Immunofluores-
cent staining for fibrillin-1 after 25 days of CM cell culture shows that the fibrillin-1 fibers are scarcely present 
as punctuated assemblies in the MFS cell culture and abundantly present in the corrected (Fig. 2). This demon-
strates the expected dysfunctional fibrillin-1 in the matrix of the MFS cell culture.
Atomic force microscopy shows that cardiomyocytes in the MFS in vitro model are stiffer. In 
the current study, an advanced quantitative imaging (QI) mode is employed on corrected and MFS cell cultures 
of (Fig. 3A,B), allowing simultaneous profiling of the surface topography and mapping of mechanical stiffness. 
Similarly as demonstrated in Fig. 1E,F, the recovery of corrected CMs is better than in MFS CMs, but both 
cultures show a beating layer of cardiomyocytes. Resulting QI images show a map of force (Fig.  3C,D) and 
height (Fig. 3E,F) of the 25 day old CMs cell cultures for corrected and MFS. Figure 3G,H project the stiffness, 
measured as the Young’s modulus, on top of the height of the cells. The CMs in this in vitro model are growing 
as a layer on top of a basal layer of cells as shown in Fig. 1E,F. The highest areas are shown as a distinct popula-
tion in the AFM (highest 25%). In the in vitro MFS model the highest areas are the stiffest, while the opposite is 
observed in the corrected cell line, where the stiffest areas are located at the lower areas (Fig. 3G,H). The AFM 
images show that on average the corrected cell culture system is stiffer than the MFS cell culture system (Fig. 3I) 
(p value < 0.0001). These measurements are performed on the complete CM cell culture, including the cells in the 
basal layer. However, AFM measurements on the upper layer of CMs, show that the MFS CMs are significantly 
stiffer than the corrected CMs (Fig. 3J) (p value < 0.0001). The stiffness of the MFS CMs compared to the com-
plete MFS cell culture where significantly stiffer (p value < 0.0001) and the corrected CMs were significantly less 
stiff compared to the complete corrected culture (p value < 0.0001).
Video analysis using Musclemotion. In order to assess if the dysfunctional fibrillin in the ECM of the 
MFS CM cell culture impaired contraction, videoclips are analyzed using the Musclemotion software (suppl. 
video 1 and suppl. video 2). The 25-day-old MFS CMs have a shorter beat-to-beat interval compared to corrected 
CMs (Fig. 4). The corrected CMs have a significantly higher contraction amplitude compared to the MFS CMs 
(p = 0.0078), indicating that the corrected in vitro culture system exerts more relative displacement compared 
to the MFS.
MEA results show distinct differences between MFS and corrected cardiomyocytes. CMs (15–
20 day old) are passaged onto the MEA and the baseline is measured after a recovery period of 5 days. Homog-
enously beating cultures were observed and used for subsequent analysis. The beat-to-beat interval, depicted by 
the RR interval, is automatically extracted from the raw data (Fig. 5A–C). The electric field potential (EFP) of 
the baseline recordings (Fig. 5A) shows that the RR interval is significantly shorter in MFS CMs than in control 
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Figure 1.  Phase contrast or immunofluorescent pictures from cell cultures of corrected (A,C,E,G) and MFS 
(B,D,F,H). hiPSC cultures have similar growth characteristics (A,B) and show expression of pluripotency 
markers OCT4 (green) and SOX2 (red) and HOECHST (blue) (C,D). Both CMs from corrected and MFS are 
growing as a layer on top of a basal layer of cells (E,F). The area of CMs in (E) and (F) is highlighted by the 
dashed line. Passaged CMs show better recovery in corrected (G) compared to MFS CMs (H) as indicated by the 
more brighter areas in corrected CMs. Scalebars indicate 500 µm. Graph (I) shows the ratio between TNNI3 and 
TNNI1 as a ratiometric marker for maturation of the CMs at day 15 and day 24, n = 3. Graph (J) represents the 
relative gene expression for TNNT2 in the cardiac model at day 24 for corrected (black) and MFS (red), n = 6.
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(p < 0.0001) and corrected CMs (p = 0.0036) (Fig. 5D). Moreover, the variation of the RR interval at baseline 
measured as SDNN shows a significant difference between MFS CMs and control (p < 0.0001) and between 
MFS CMs and corrected CMs (p = 0.0031) (Fig. 5E). The SDSD also differs significantly between MFS CMs and 
control (p < 0.0001) and between MFS CMs and corrected CMs (p = 0.0045) (Fig. 5F). The coefficient of vari-
ance, which compensates for the difference in beat rate, also shows significantly less variance of the MFS CMs at 
baseline compared to control-CMs (p = 0.0007) and the corrected CMs (p = 0.0014) (Fig. 5G). The poincaré plot 
from three representative replicates per cell line shows that the RR intervals of MFS CMs cluster tightly together, 
while both control and corrected CMs show greater variations (Fig. 5H). This indicates that the MFS CMs show 
less beat-to-beat variability at baseline in comparison to corrected and control.
The effect of serial ISO treatment on CMs is measured using MEA. The EFP signals show that the control CMs 
beat significantly faster in response to higher concentrations (10 nM and 100 nM) of ISO (Fig. 5B,C). The RR 
interval of control CMs decreases with a higher concentration of ISO (Spearman’s rank correlation = 0.77) but a 
minimal and non-significant effect of ISO on the RR interval is observed for corrected and MFS CMs (Fig. 6A). 
Although both have a perfect correlation between the RR interval and the ISO concentration as indicated by 
Spearman’s rank correlation of 1. The beat-to-beat variation, as indicated by the SDNN (Fig. 6B) is significantly 
decreased for control CMs as a result of ISO treatment but no significant difference is observed for MFS CMs. 
For corrected CMs only a significant decrease is observed at 50 nM ISO treatment. The SDSD (Fig. 6C) is 
significantly decreased for the control at all the ISO concentrations and for corrected CMs only at 50 nM ISO 
treatment. While no significant effect for SDNN and SDSD is obtained for the MFS CMs, both parameters seem 
to increase in variation while the opposite is observed for both control and corrected CMs in response to ISO 
stress. Figure 6D shows the coefficient of variance relative to the baseline. This figure shows that the variation of 
the beat-to-beat interval increases in MFS CMs in response to ISO, however not significantly. The variance of the 
RR interval of both the control and corrected CMs remains similar after exposure to increased ISO concentra-
tions when compared to baseline conditions.
Chronic isoproterenol treatment reveals structural defects in ECM of MFS cell culture. In 
order to test whether the fibrillin defect influences the CM culture morphology, the global architecture of fibril-
lary fibronectin deposited in the culture is visualized in 24-day-old cultures. To increase stress on the CMs, a 
treatment with 1 µM ISO was performed for 7 days, starting in cultures of 17 days old. The cell cultures present 
a higher abundance of fibronectin in areas of CMs, indicated by the cTnT staining, after ISO treatment com-
pared to untreated controls (Fig. 7). In the untreated controls there is relative less fibronectin deposition in the 
areas of the CMs. Quantification of the average intensity of cTnT shows a significant reduction in ISO-treated 
Figure 2.  Immunohistochemical staining for fibrillin-1 on CM cell culture for corrected and MFS. Fibrillin-1 
in red and nuclei stained with HOECHST in blue after 25 days after the start of cardiac differentiation. 
Fibrillin-1 microfibrils or punctate assemblies are observed in corrected or MFS cultures, respectively. The 
average fluorescent intensity of fibrillin-1 in this image is respectively 26.65 and 19.51 for corrected and MFS 
cell culture. Orthogonal view shows the z-section of the area, indicated with the arrow in the overlay image. Bar 
indicates 100 µm.
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16756  | https://doi.org/10.1038/s41598-020-73802-w
www.nature.com/scientificreports/
Figure 3.  Atomic Force Microscopy of 25-day-old cardiomyocytes: phase-contrast images of corrected (A) and MFS (B) cell cultures 
the mechanical stiffness mapping for corrected (C) and MFS (D) and the topography mapping of the (height) for corrected (E) and MFS 
(F) (colours: red is stiff, blue is more elastic) for corrected (C) and MFS (D) cells. Annotation of cell border (green line) and nuclear area 
(blue) in (E) and (F). Mechanical stiffness mapping is overlaid with topography mapping for corrected (G) and MFS (H). Dimensions 
are indicated in µm. AFM was performed on three independent cultures for each cell line. Large scale measurements of the complete 
CM cell cultures show a higher average Young’s modulus for the corrected (black) cell culture in comparison to MFS (red) (p < 0.0001) 
(I). The CMs from MFS show a higher Young’s modulus compared to corrected CMs when only the 25% highest areas, composed of 
CMs, were measured (p < 0.0001) (J). The bars in (I) and (J) indicate the standard deviation. The level of significance is indicated by 
asterisks: p values less than 0.001 are indicated with three asterisks. Bar in panel (A) and (B) indicates 500 µm.
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versus non-treated MFS cell culture (Fig. 7 and suppl. Figure 3). A trend for increased fibronectin deposition 
is observed after ISO treatment for MFS CMs, although not significant. No significant reduction for cTnT nor 
fibronectin deposition is observed for corrected cell culture.
Stretching of cell cultures leads to diminished level of MFS cardiomyocytes. Another set of 
experiments aim to create a dynamic strain on the CMs with a cyclic strain frequency to mimic the strain expe-
rienced by CMs in the myocardium using a Flexcell tension system on 25-day old-CMs. After 6 h and 40 h of 
stretching, cell cultures are stained for cardiac marker cTnT. MFS CMs appear less abundant after stretching and 
the layer of cells that are left appears impaired as indicated by more individual cTnT-positive cells (Fig. 8). The 
stress caused by stretching has no impact on the structural integrity of the CMs in the corrected cell culture.
Substrate stiffness has no influence on beating rate of MFS cardiomyocytes. Different substrate 
stiffness are used in this study, for MEA measurements glass (≈ 10 GPa), for AFM plastic (≈ 0.1 GPa) and for 
Flexcell a flexible membrane (≈ 150 kPa). The beat rate of CMs is analyzed to determine if different substrate 
stiffness has an influence on the functional behavior of the CMs. Significant differences in beat rate between cor-
rected and MFS CMs are observed in case of flexible membrane (p = 0.006) and glass (p = 0.0036) (Fig. 9). When 
comparing the effect of the substrate on the beat rate of corrected CMs, significant difference between glass and 
flexible (p = 0.0022) and between plastic and flexible membrane (p < 0.0001) are observed. No significant differ-
ences in beat rate between the substrates are present for MFS CMs.
Discussion
In literature there is accumulating evidence of MFS related cardiomyopathy. De Backer et al. reported primary 
impairment of the left ventricle unrelated to valvular  disease31. Hetzer et al. described primary cardiomyopa-
thy in 3% and secondary cardiomyopathy in 8% of MFS patients, which is more common than in the general 
 population32. FBN1 appears to be an effector of MFS cardiomyopathy, however these studies also warrant the 
necessity for a better understanding of the mechanisms responsible. Furthermore, another study demonstrates 
the high prevalence of ventricular arrhythmia in 48% of MFS  patients17.
Data obtained in humans have been corroborated in several mouse  models13,33–35. These findings also provide 
evidence for intrinsic myocardial dysfunction. Several mouse models for MFS have been established which 
resulted in increased knowledge about pathogenic pathways involved in MFS. However, there are important dif-
ferences between mice and humans both genetically and physiologically, especially concerning the cardiovascular 
system. The hiPSC technology provides the opportunity to obtain difficult to access cell types such as CMs in a 
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Figure 4.  Video analysis of the beating of cardiomyocytes using Musclemotion was performed on corrected 
(n = 3, black) and MFS cell cultures (n = 3, red). The representative plots show differences in contraction 
amplitude. The bar graph shows the average contraction amplitude of three independent experiments per cell 
line and shows a significant difference (p = 0.0078), error bars represent the standard error in the bar graph. The 
level of significance is indicated by asterisks: p values less than 0.01 indicated with two asterisks.
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Figure 5.  MEA measurements of the extracellular field potentials for the control line (H9), the corrected CMs 
and the MFS CMs after 20–25 days after start of cardiac differentiation. (A) The baseline measurements without 
the addition of isoproterenol (ISO). The extracellular field potentials are shown for 10 nM (B) and 100 nM ISO 
(C). The bar plots show the differences between control, corrected and MFS CMs for RR interval (D), SDNN 
(E), SDSD (F) and coefficient of variance (G). Corrected CMs (n = 9, black), MFS CMs (n = 8, red). Poincaré plot 
from three representative replicates of the control (blue), corrected (black) and MFS CMs (red) (H). The three 
clusters of MFS are magnified in the right corner of figure (H). The level of significance is indicated by asterisks: 
p values less than 0.001 are indicated with three asterisks and p values less than 0.01 indicated with two asterisks.
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patient-specific manner, recapitulating the disease but missing some of the in vivo  complexity36. In vitro derived 
CMs from hiPSCs have led to an increased understanding of various cardiomyopathies, including structural 
cardiomyopathies such as hypertrophic cardiomyopathy and other cardiomyopathies such as arrhythmogenic 
 cardiomyopathy37.
Several hiPSC derived cell models for MFS have been established so far, modelling different aspects of the 
disease. The skeletogenic phenotype of MFS including osteogenic differentiation has been modeled in vitro38 
and cell models for the vascular involvement in MFS were established by differentiating hiPSCs to vascular 
smooth muscle  cells25,39. The skeletogenic model for MFS revealed impaired osteogenic differentiation as a 
result of increased TGF-β activation, and up-regulation of ECM markers PAI-1 and collagen was  observed38. 
In the vascular smooth muscle model for MFS, a reduced contractile phenotype was observed in response to 
 carbachol25,39. The vascular smooth muscle model also showed an increase in PAI-1 on mRNA level as a conse-
quence of increased TGF-β signaling. Furthermore, the model showed specific differences in TIMP and MMP 
expression. Another in vitro study revealed that cultured fibroblast from skin biopsies have lower collagen and 
elastin gene expression in MFS compared to healthy  volunteers40.
In this current study, we report the first, to the best of our knowledge, in vitro model for the MFS myo-
cardium by differentiating hiPSCs to CMs. Functional experiments compared CM cell cultures derived from 
hiPSCs carrying a pathogenic variant in FBN1 with CM cell cultures derived from the isogenic hiPSCs, where 
the pathogenic variant is CRISPR-Cas9 corrected. Corrected hiPSCs and MFS hiPSCs have comparable growth 
characteristics, and can be cultured in a similar manner (Fig. 1A,B). Based on the expression of the pluripotency 
markers OCT4 and SOX2, we can conclude that the pluripotency of the stem cells with the pathogenic variant 
in FBN1 is unaffected (Fig. 1C,D), which is also described by Granata et al.25.
Also, FBN1 did not affect the cardiac differentiation potential in this study and contraction of both cor-
rected and MFS CMs is observed after 8–12 days after the start of differentiation. To assess cardiac maturation 
a molecular signature based on TNNI isoform expression of TNNI1 (ssTnI, fetal) and TNNI3 (cTnI, adult) was 
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Figure 6.  MEA measurements of control, corrected and MFS CMs after treatment with serial isoproterenol 
(ISO) concentrations of 5, 10, 25, 50 and 100 nM. Bar plots show differences between the three lines at each ISO 
concentration for RR interval (A), SDNN (B), SDSD (C) and the coefficient of variance presented as factor of 
the baseline (D). The Spearman’s rank correlation is indicated in panel A. Corrected CMs (n = 6, black), MFS 
CMs (n = 7, red), H9 control (n = 5, blue).
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Figure 7.  Cell-deposition of fibronectin. Chronic isoproterenol (ISO) treatment (1 µM) for 7 days for both 
MFS and corrected cell cultures is compared with no treatment using immunohistochemistry staining for cTnT 
and fibronectin, nuclei visualised with HOECHST. Bar indicates 100 µm. Bar graphs show average fluorescent 
intensity of cTnT and fibronectin for corrected (n = 3, black) and MFS (n = 3, red) with ISO treatment and 
no treatment. The level of significance is indicated by asterisks: p values less than 0.05 are indicated with one 
asterisk.
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 evaluated41. The maturation of MFS CMs seems to be hampered initially at day 15 when compared to corrected 
CMs, although not significantly (p = 0.074) (Fig. 1I). At day 24, the maturation status of the MFS CMs increased 
to a similar level as the corrected CMs. Similar gene expression of the cardiac specific gene TNNT2 in the 
24-days-old cultures (Fig. 1J) indicate a similar culture composition of CMs. Maturation of CMs is linked to 
their extracellular environment. The initial lack of maturation in MFS CMs could result from a dysfunctional 
matrix leading to decreased β1 integrin receptor activation and decreased focal adhesion kinase  activity42. The 
herein presented cardiac in vitro model is composed of predominantly CMs which are growing in a contracting 
layer on top of a basal layer. Gene expression analysis reveals that both TIMP1 and KLF4 increase significantly at 
day 24 compared to day 15 in corrected CMs (Suppl. Figure 2). KLF4, PAI-1 and FBN1 expression significantly 
increases at day 24 compared to day 15 in MFS CMs. The morphology and characteristics of this CM cell culture 
system corresponds to previous described cardiac differentiations from mono-layer hiPSCs, as was first described 
by Lian and coworkers in  201243.
Figure 8.  Stretching of in vitro cells to analyse structural integrity of the MFS CMs. Fluorescent images of 
immunohistochemistry staining for cTnT (green) after 6 h and 40 h of stretching using Flexcell and unstretched 
control (on membrane) for both MFS and corrected CMs. Bar plot shows the average intensity of cTnT in 
corrected (black) and MFS (red) CMs and includes the standard deviation. Bar = 100 µm.
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The recovery and attachment after passaging is adequate in the corrected CMs (Fig. 1G). Normal fibril-
lin-1 and β1 integrin play an important role in the adhesion of  CMs44. The fibrillin-1 deposition in the matrix 
of corrected CMs is normal (Fig. 2). AFM measurements confirmed that the matrix was stiffer than the CMs 
and indicate that the matrix is well developed in the corrected CMs. However, the recovery and attachment of 
the passaged MFS CMs is reduced compared to corrected CMs (Fig. 1H). The FBN1 mutation in this model 
recapitulates an abnormal matrix as becomes clear from the fibrillin-1 deposition (Fig. 2). Measurements with 
AFM further elucidate a lesser developed matrix in the MFS cardiac model compared to the corrected model 
(Fig. 3). The perturbed matrix in the MFS cardiac model provides less support to the cell culture and could 
explain why the MFS CMs have more difficulty attaching. Collagen bundles are formed in the MFS cell culture 
as a potential response to the impaired fibrillin-1 deposition (Suppl. Figure 4), which may further impact the 
behavior of MFS CMs.
CMs in this in vitro cardiac model contract spontaneously. However, the MFS CMs show a reduced contrac-
tion amplitude compared to corrected CMs in the video analysis (Fig. 4). This finding is consistent with previ-
ous observations in smooth muscle cells of  MFS25. AFM measurements reveal that the MFS CMs are stiffer in 
comparison to the corrected (Fig. 3), this could explain their reduced contraction amplitude.
A higher spontaneous beating rate in MFS CMs was observed with MEA measurements when compared 
to corrected CMs (Fig. 5). This divergence could be explained by the differences in the ECM composition as 
indicated by AFM measurements, since the ECM influences the beating rate of in vitro  CMs45. The effect of the 
substrates used in this study with different stiffness; glass (MEA, ≈ 10 GPa), plastic (AFM, ≈ 0.1 GPa) and flexible 
(Flexcell, ≈ 150 kPa), on the beating rate of CMs was further investigated. Corrected CMs were influenced by the 
substrate and have a significantly smaller RR interval when cultured on a flexible membrane compared to glass 
(Fig. 9). Previous studies also concluded that the optimal stiffness of the substrates (between 10 and 30 kPa) for 
CMs is important for their normal phenotype and that CMs beat faster when cultured on substrates with a lower 
 stiffness46,47. However, MFS CMs did not show a different beating rate at the different substrates. The abnormal 
fibrillin-1 in MFS cultures is thought to disconnect the CMs from their extracellular environment.
Interestingly, the variation in the beating rate as measured with MEA was high in the corrected CMs, while 
the CMs from MFS were beating with little variation (Fig. 5). This arrhythmogenic behavior of the corrected 
CMs was replicated with CMs derived from the hESC H9 control line. MEA measurements on fibronectin coated 
glass substrate have been reported to cause more beating variation, compared to more ideal culture systems such 
as  hydrogels48, that more closely resemble the in vivo extracellular environment. Since the ECM is assumed to 
be abnormal in MFS, it could be suggested that the MFS CMs receive less mechanical feedback signals from the 
environment, explaining the small amount of variation in beat  rate49. Other studies describe that CMs derived 
from hiPSCs and hESCs exhibit intrinsic beat rate variability resembling pacemaker cells in the adult heart 
without the autonomic nerve system being present in the in vitro  system50,51. This suggest an intrinsic cardiac 
regulatory mechanism which is thought to be influenced by dynamic structural, biochemical and intracellular 
changes. For instance, single CMs have a higher beat-to-beat rate variability compared to CMs in embryoid 
body  configuration52.
ISO mimics increased sympathetic nerve activity and stress. The acute response to ISO did not show a sig-
nificant decrease in the RR interval for the corrected and MFS CMs, but showed a perfect correlation between 
increasing ISO concentration and decreasing RR interval (Fig. 6). The variation of the RR interval decreased in 
the corrected CMs and increased in the MFS CMs. The impact of chronic stress, which mimics advanced heart 
failure by means of chronic ISO treatment was more extensive on the MFS CMs (Fig. 7). Immunofluorescent 
staining showed that the cTnT was significantly reduced after ISO treatment in the MFS cell culture but main-
tained in the corrected cell culture. The overall fibronectin deposition remained similar after ISO treatment. 
However, at the locations of diminished cTnT signal a trend for increased fibronectin deposition was observed. 
We postulate that the CMs in these areas experience the most severe stress. Fibronectin co-localizes with fibril-
lin-1 and is essential for the formation of  microfibrils53. β1 integrin is important in the connection between the 
matrix and CMs and is also implicated in the response to beta adrenergic stimulation as an important transmit-
ter of this  stress54. The deposition of fibronectin is important for a healthy response to the increased stress and 
thus a demand for more structural support of the ECM as is observed in the corrected cell-culture. The lack of 
Figure 9.  RR interval of corrected (black) and MFS (red) CMs measured on different substrate stiffnesses: 
glass (≈10 GPa) n = 8, plastic (≈0.1 GPa) n = 3 and on a flexible Flexcell membrane (≈150 kPa) n = 6. Error bars 
represent the standard error in the bar graphs. The level of significance is indicated by asterisks: p values less 
than 0.001 are indicated with three asterisks and p values less than 0.01 indicated with two asterisks.
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structural support in the MFS cell culture could lead to the more disrupted appearance of the MFS CMs observed 
after the ISO treatment or even CM cell  death54.
Rouf and colleagues discovered that in the Fbn1c1039G/+ mouse model for MFS, the unstressed heart did not 
reveal cardiac structural or functional  abnormalities34. Only when increased hemodynamic load was posed on 
the hearts of these mice by means of transverse aortic constriction, ventricular dilatation and dysfunction was 
observed. This coincides with the Flexcell results. Flexcell revealed in the in vitro cardiac model that the MFS 
CMs were less abundantly present after stretching and that the monolayer seemed to be impaired after stretching 
(Fig. 8). The MFS CMs seem more prone to this simulated hemodynamic stress, likely caused by their weaker 
ECM unable to handle the mechanical stimuli, unlike the corrected CMs. This confirms that fibrillin-1 is essential 
for a normal response to increased mechanical load.
Taken together, the deposition of fibrillin-1 in the ECM was disrupted in the described in vitro cardiac model 
for MFS and is thought to be the driving force for the observed abnormalities. The findings in this study coincide 
with the conclusions made by Cook and colleagues that fibrillin-1, present in the ECM, is important to adapt 
the CMs to increased  stress14. This implies that CMs with dysfunctional fibrillin-1 will not adapt as well to stress 
compared to corrected CMs. Our findings suggest that the MFS CMs are more disconnected from their ECM 
environment, possibly via decreased β1 integrin levels. This would impair correct sensing of increased stress 
from the ECM to the CMs and vice versa.
The observed abnormalities in our in vitro cardiac model for MFS could have a detrimental effect on func-
tioning of the heart as a whole. A subset of patients develop MFS related cardiomyopathy, but the mechanism 
is still unclear. MFS CMs in our model prove to be much more vulnerable to stress in comparison to corrected 
CMs. This poses the idea that MFS related cardiomyopathy is stress-induced, possibly caused by impaired and 
less supportive matrix. However, it should be considered that this in vitro cardiac model may oversimplify the 
in vivo situation in MFS and does not account for all the complexity of the syndrome. The impairment of the 
MFS CMs could occur in another, much slower fashion in vivo. The stress posed on the in vitro CMs by means 
of ISO and Flexcell could be an exaggeration of the stress actually present in a human being, but was used to 
evoke a potential response. This proof of concept study (one mutation) reveals distinct differences in the MFS 
CMs compared to the isogenic control by the use of functional assessments. Moreover, the established model 
could form the fundamental support for future research. Exploration of the observed abnormal behavior of 
MFS CMS is warranted and should address the behavior of CMs on a cell level in terms of sarcomere structure 
and deformation.
The complex pathologic mechanisms that drive MFS remain unclear, and in this study the highly variable 
phenotype caused by over 3000 known pathogenic variants in FBN1 gene and its impact on the functional 
characteristics of the CMs is not addressed. This proof of concept study provides evidence that CMs show 
abnormal behavior in the context of MFS using different functional characterization methods. We postulate 
that impaired mechanosensing via β1 integrin could explain the observed results, but this mechanism should be 
further elucidated. However, it remains to be answered if the defects in the ECM are solely driving the observed 
functional differences in the CMs, or if the CMs contribute as well. This warrants further investigation into 
MFS cardiomyopathy. The described in vitro cardiac model for MFS demonstrates phenotypic differences in 
the MFS CMs, providing an interesting platform to further study disease mechanisms and for the assessment 
of new therapies for MFS.
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